Catalent to purchase Italy manufacturing facility from BMS

Bristol-Myers Squibb has reached an agreement with Catalent for the latter to acquire its Anagni, Italy-based facility which specialises in the manufacturing and packaging of oral solid, biologics, and sterile products, it has emerged.

The facility has been a primary platform from which BMS launched a slew of its drugs, in particular in the treatment of cancer and cardiovascular disease.

read more

Original Article: Catalent to purchase Italy manufacturing facility from BMS

More From BioPortfolio on "Catalent to purchase Italy manufacturing facility from BMS"